TVTX vs. TGTX

Last updated Apr 2, 2026

Compare and contrast key facts about Travere Therapeutics, Inc. (TVTX) and TG Therapeutics, Inc. (TGTX).

Performance

TVTX vs. TGTX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Travere Therapeutics, Inc. (TVTX) and TG Therapeutics, Inc. (TGTX). The values are adjusted to include any dividend payments, if applicable.

TVTX vs. TGTX - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
TVTX Travere Therapeutics, Inc.	-17.77%	119.35%	93.77%	-57.25%	-32.25%	13.89%	91.94%	-37.25%	7.40%	11.30%
TGTX TG Therapeutics, Inc.	12.65%	-0.96%	76.23%	44.38%	-37.74%	-63.48%	368.65%	170.73%	-50.00%	76.34%

Fundamentals

EPS TVTX : -$0.53 TGTX : $2.77
PS Ratio TVTX : 6.02 TGTX : 10.21
Total Revenue (TTM) TVTX : $490.73M TGTX : $531.90M
Gross Profit (TTM) TVTX : $462.25M TGTX : $453.87M
EBITDA (TTM) TVTX : -$2.08M TGTX : $115.24M

Returns By Period

In the year-to-date period, TVTX achieves a -17.77% return, which is significantly lower than TGTX's 12.65% return. Over the past 10 years, TVTX has underperformed TGTX with an annualized return of 8.14%, while TGTX has yielded a comparatively higher 14.12% annualized return.

TVTX

• 1D: 5.76%
• 1M: 6.40%
• YTD: -17.77%
• 6M: 26.74%
• 1Y: 80.16%
• 3Y*: 11.79%
• 5Y*: 4.07%
• 10Y*: 8.14%

TGTX

• 1D: 1.08%
• 1M: 14.22%
• YTD: 12.65%
• 6M: -8.15%
• 1Y: -11.05%
• 3Y*: 30.70%
• 5Y*: -7.26%
• 10Y*: 14.12%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

TVTX vs. TGTX — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

TVTX

TVTX Risk / Return Rank: 75
TVTX Sharpe Ratio Rank: 77
TVTX Sortino Ratio Rank: 75
TVTX Omega Ratio Rank: 75
TVTX Calmar Ratio Rank: 78
TVTX Martin Ratio Rank: 71

TGTX

TGTX Risk / Return Rank: 30
TGTX Sharpe Ratio Rank: 30
TGTX Sortino Ratio Rank: 28
TGTX Omega Ratio Rank: 29
TGTX Calmar Ratio Rank: 30
TGTX Martin Ratio Rank: 32

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

TVTX vs. TGTX - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Travere Therapeutics, Inc. (TVTX) and TG Therapeutics, Inc. (TGTX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	TVTX	TGTX	Difference
Sharpe ratio Return per unit of total volatility	1.20	-0.24	+1.45
Sortino ratio Return per unit of downside risk	1.88	-0.02	+1.90
Omega ratio Gain probability vs. loss probability	1.25	1.00	+0.26
Calmar ratio Return relative to maximum drawdown	2.18	-0.35	+2.53
Martin ratio Return relative to average drawdown	3.75	-0.53	+4.28
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

TVTX vs. TGTX - Sharpe Ratio Comparison

The current TVTX Sharpe Ratio is 1.20, which is higher than the TGTX Sharpe Ratio of -0.24. The chart below compares the historical Sharpe Ratios of TVTX and TGTX, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	TVTX	TGTX	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	1.20	-0.24	+1.45
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.06	-0.08	+0.15
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.14	0.16	-0.02
Sharpe Ratio (All Time) Calculated using the full available price history	0.26	-0.05	+0.31

Correlation

The correlation between TVTX and TGTX is 0.36, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

TVTX vs. TGTX - Dividend Comparison

Neither TVTX nor TGTX has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

TVTX vs. TGTX - Drawdown Comparison

The maximum TVTX drawdown since its inception was -85.43%, smaller than the maximum TGTX drawdown of -99.52%. Use the drawdown chart below to compare losses from any high point for TVTX and TGTX.

Drawdown Indicators

	TVTX	TGTX	Difference
Max Drawdown Largest peak-to-trough decline	-85.43%	-99.52%	+14.09%
Max Drawdown (1Y) Largest decline over 1 year	-34.61%	-42.01%	+7.40%
Max Drawdown (5Y) Largest decline over 5 years	-83.12%	-92.36%	+9.24%
Max Drawdown (10Y) Largest decline over 10 years	-83.64%	-93.19%	+9.55%
Current Drawdown Current decline from peak	-22.00%	-85.61%	+63.61%
Average Drawdown Average peak-to-trough decline	-41.61%	-91.55%	+49.94%
Ulcer Index Depth and duration of drawdowns from previous peaks	20.07%	28.02%	-7.95%

Volatility

TVTX vs. TGTX - Volatility Comparison

Travere Therapeutics, Inc. (TVTX) and TG Therapeutics, Inc. (TGTX) have volatilities of 14.80% and 15.01%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	TVTX	TGTX	Difference
Volatility (1M) Calculated over the trailing 1-month period	14.80%	15.01%	-0.21%
Volatility (6M) Calculated over the trailing 6-month period	43.14%	28.15%	+14.99%
Volatility (1Y) Calculated over the trailing 1-year period	66.95%	46.37%	+20.58%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	64.56%	87.52%	-22.96%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	56.99%	86.93%	-29.94%

Financials